Preliminary data suggestive of a novel translational approach to mesothelioma treatment: Imatinib mesylate with gemcitabine or pemetrexed

Thorax

Volumn 62, Issue 8, 2007, Pages 690-695

  Bertino, Pietro ^a   Porta, Camillo ^b   Barbone, Dario ^a   Germano, Serena ^a   Busacca, Sara ^a   Pinato, Sabrina ^a   Tassi, Giancarlo ^c   Favoni, Roberto ^d   Gaudino, Giovanni ^a   Mutti, Luciano ^e  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c Brescia Civic Hospital   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e Local Health Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; IMATINIB; PEMETREXED; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; DEOXYCYTIDINE; GENES, FMS; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; PIPERAZINES; PLEURAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 34547765871     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2006.069872     Document Type: Article

References (43)

1. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72.
2. Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet 2004;364:1183-5.
3. Pass HI, Vogelzang N, Hahn S, et al. Malignant pleural mesothelioma. Curr Probl Cancer 2004;28:93-174.
4. Klominek J, Baskin B, Liu Z, et al. Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor. Int J Cancer 1998;76:240-9.
5. Cacciotti P, Libener R, Betta P, et al. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 2001;98:12032-7.
6. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-75.
7. Cacciotti P, Strizzi L, Vianale G, et al. The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol 2002;26:189-93.
8. Hoang CD, Zhang X, Scott PD, et al. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res 2004;64:7479-85.
9. Garlepp MJ, Leong CC. Biological and immunological aspects of malignant mesothelioma. Eur Respir J 1995;8:643-50.
10. Longerak AW, van der Linden-van Beurden CA, Versnel MA. Regulation of differential expression of platelet-derived growth factor alpha- ana beta-receptor mRNA in normal and malignant human mesothelial cell lines. Biochim Biophys Acta 1996;1305:63-70.
11. Pogrebniak HW, Lubensky IA, Pass HI. Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future therapies? Surg Oncol 1993;2:235-40.
12. Klominek J, Baskin B, Hauzenberger D. Platelet-derived growth factor (PDGF) BB acts as a chemoartractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction. Clin Exp Metastasis 1998;16:529-39.
13. Horvai AE, Li L, Xu Z, et al. c-Kit is not expressed in malignant mesothelioma. Mod Pathol 2003;16:818-22.
14. Butnor KJ, Burchette JL, Sporn TA, et al. The spectrum of Kit (CD117) immunoreactivity in lung and pleural rumors: a study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med 2004;128:538-43.
15. Catalano A, Rodilossi S, Rippo MR, et al. Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. J Biol Chem 2004;279:46706-14.
16. Lanfrancone L, Boraschi D, Ghiara P, et al. Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor (CSF), granulocyte-monocvte-CSF, macrophage-CSF, interleukin-1 (IL-1), and IL-6) and are activated and stimulated to grow by IL-1. Blood 1992;80:2835-42.
17. Taylor JR, Brownlow N, Domin J, et al. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 2006;25:147-51.
18. Kindler HL. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer 2004;45(Suppl 1):S125-7.
19. Shih AH, Holland EC. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 2006;232:139-47.
20. Johnson MD, Okedli E, Woodard A, et al. Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. J Neurosurg 2002;97:668-75.
21. Cacciotti P, Barbone D, Porta C, et al. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 2005;65:5256-62.
22. George D. Platelet-derived growth factor receptors: a therapeutic target in solid rumors. Semin Oncol 2001;28(5 Suppl 17):27-33.
23. Abou-Jawde R, Choueiri T, Alemany C, et al. An overview of targeted treatments in cancer. Clin Ther 2003;25:2121-37.
24. Roberts F, Harper CM, Downie I, et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116:253-62.
25. Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007;59:149-50.
26. Mathy A, Baas P, Dalesio O, et al. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005;50:83-6.
27. Pierras K, Stumm M, Hubert M, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003;9:3779-87.
28. Yokoi K, Sasaki T, Bucana CD, et al. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcirabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 2005;65:10371-80.
29. Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 2004;45(Suppl 1):S103-19.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
31. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001;298:865-72.
32. Tallarida RJ. Statistical analysis of drug combinations for synergism. Pain 1992;49:93-7.
33. Feng FY, Varambally S, Tomlins SA, et al. Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 2007;17:3431-9.
34. Stein RC. Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer 2001;8:237-48.
35. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7.
36. Rascoe PA, Cao X, Daniel JC, et al. Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma. J Thorac Cardiovasc Surg 2005;130:393-400.
37. Krystal GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319-26.
38. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000;19:3521-8.
39. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
40. Gonzalez I, Andreu EJ, Panizo A, et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004;10:751-61.
41. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
42. Vogelzang NJ, Porta C, Mutti L. New agents in the management of advanced mesothelioma. Semin Oncol 2005;32:336-50.
43. Beppu K, Jaboine J, Merchant MS, et al. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004;96:46-55.